Tag: Coronavirus Outbreak

  • Good samaritan compiles list of breast milk donors for infants who lost mothers to COVID-19

    By PTI
    NEW DELHI: In a novel initiative, an activist is compiling a list of women willing to donate their breast milk for infants who have lost their mothers to coronavirus.

    The move comes after many such requests for breast milk were received on social media.

    Activist Anvy Shrivastava with the help of the Delhi government’s health department is compiling such a list of breast milk donors.

    “We got few requests of breast milk for infants who lost their mothers to the infection. Milk banks usually provide 30 ml of breast milk for Rs 300, but it cannot be afforded by underprivileged families.

    “We are getting donors and we specifically ask them if they have stored colostrum. We are maintaining a database of such donors. Most of these donors are from privileged backgrounds. They store the milk as per their doctors’ advice,” Shrivastava told PTI.

    She said her team gets breast milk requests from attendants of infants admitted in neonatal ICUs.

    Some of these infants are breastfed by women who had recently given birth at the same hospital, she said.

    “The Delhi government’s health department is backing us. At present, we have around 20 donors. We have asked them to store the breast milk datewise. We collect the milk from them and send it to a milk bank where it is screened. The criteria for a donor is that she should not be suffering from any ailment or be COVID-19 positive,” the activist said.

    The initiative caught everyone’s attention after various mother community groups talked about it on Telegram along with being noticed on Instagram and Twitter.

    “We require colostrum which is produced by a mother in the initial days after she gives birth. Some mothers produce colostrum even before the birth of the child. We have few donors for colostrum,” Srivastava said.

    Freshly expressed or pumped milk can be stored in the refrigerator for up to four days and in the freezer for about six months.

    “We are preparing for the days ahead. Anticipating that underprivileged families might need it (breast milk) and there can be a similar crisis in the future, we are preparing a database of donors,” she said.

    The Delhi Commission For Protection of Child Rights also said that it received many requests for breast milk amid the pandemic.

    Raghuram Mallaiah, director, Neonatology Fortis La Femme and Founder, Amaara human milk bank, Delhi and Bengaluru said, “During the pandemic, we got requests from two to three hospitals where babies were born premature and their COVID-19 positive mothers were on ventilator. We also provided breast milk to such babies at our hospital.”

    However, he said there has been a dip in the number of donors amid the pandemic outbreak.

    “During pre-Covid times, we had 40-45 litres and even 50 litres of breast milk in our bank, but due to the fear of COVID-19, donor mothers now do not want to step out and also do not want anyone to come and visit them. Till February-March, we were doing fine, but after that we have had few donations and hardly get 15-20 litres a month. We even had to say no to a couple of hospitals with such requests,” he said.

    The hospital used to donate 40 bottles of breast milk to Maulana Azad Medical College (MAMC), but the Covid situation has led us to discontinue it, he added.

  • MHA orders continuation of COVID guidelines till June-end; asks states to focus on local curb strategy

    By PTI
    NEW DELHI: The Centre on Thursday directed states and union territories to continue the ongoing COVID-19 guidelines till June 30 and asked them to go for intensive and local containment measures in districts with a high number of cases to check the spread of the deadly disease.

    In a fresh order, Union Home Secretary Ajay Bhalla said strict implementation of containment and other measures has led to a declining trend in the number of new and active cases, across states and union territories, barring some areas in the southern and northeastern regions.

    “I would like to highlight that in spite of the declining trend, the number of active cases presently is still very high. It is, therefore, important that containment measures may continue to be implemented strictly.

    “Any relaxation by states and UTs, may be considered at an appropriate time, in a graded manner, after assessing the local situation, requirements and resources,” Bhalla said in his order issued to chief secretaries of the states and union territories.

    He said the guidelines issued on April 29 for the month of May will continue till June 30.

    According to the guidelines, the home ministry told the states to take necessary action to ensure sufficient oxygen-supported beds, ICU beds, ventilators, ambulances including creation of makeshift hospitals, oxygen, as needed, besides sufficient quarantine facilities.

    The home ministry, however, did not mention anything about the imposition of lockdown anywhere in the country in the fresh guidelines issued in view of the pandemic.

    The fresh guidelines for COVID-19 management came amid some decline in the daily count of the coronavirus cases and improvements in the situation of the availability of the beds, ICU and oxygen in some parts of the country like Delhi.

    India’s COVID-19 infection tally climbed to 2,73,69,093 as 2,11,298 more people tested positive for the disease in a day, while the country’s recovery went up to 90 per cent, according to the Union health ministry on Thursday.

    The death toll due to the disease rose to 3,15,235 with 3,847 fresh fatalities being reported in a span of 24 hours, the data updated at 8 am showed.

  • Inadequate info provided by vaccine marketing firms: Maharashtra Health Minister Rajesh Tope

    By PTI
    MUMBAI: Maharashtra health minister Rajesh Tope on Thursday said marketing agencies of four vaccine firms have responded to states global tender for procuring COVID-19 shots, but information provided by them is inadequate and the government has sought more details.

    The Maharashtra government has floated a global tender to procure COVID-19 vaccines to tide over a shortage of jabs.

    Speaking to reporters here, Tope said “Pfizer, Johnson & Johnson, Sputnik and AstraZeneca have submitted their tenders through their marketing agencies.

    “Some companies did not fill in the rates, while some companies have not made clear what the (supply) schedule will be like. That is why they are being asked queries (on these issues).”

    Pfizer has told some states like Punjab that they won’t supply vaccines to the states but will give them to the Centre.

    On the issue of imports, the Centre has so far allowed only Covishield, Covaxin and Sputnik.

    Will the Centre give permission to Pfizer, Moderna, Johnson & Johnson is an issue which is under the Centre’s jurisdiction.

    Tope reiterated his demand for the Union government’s intervention to buy vaccines from the international market.

    “There should be a proper national policy on vaccine imports. I wish to make this request to (Union health minister) Harsh Vardhan,” he said.

    Responding to a question, Tope listed out varying rate details provided by some of the marketing agencies. Sputniks rates are quoted in the range of USD 10 and USD 18. Pfizer rates are quoted between USD 23 and 25. In terms of rupees, the price range is from Rs 750 to Rs 1,800,” he said.

  • COVID-19: Healthcare workers attacked in Punjab’s Ludhiana

    By PTI
    LUDHIANA: A team of Punjab’s health department on Thursday was allegedly attacked in Rachhin village here when it went there to sensitise villagers about COVID-19 testing, officials said.

    A member of the team, identified as Suraaj Mohammed, a multipurpose health worker, sustained injuries on his forehead in the attack, they said, adding he was rushed to Community Health Centre in Pakhowal.

    “I was attacked with a brick by one villager named Jaspreet Singh when I was sensitising villagers to come forward for COVID-19 testing,” Mohammed told police.

    Ludhiana Deputy Commissioner Varinder Kumar Sharma said such incidents were unwarranted.

    Strict action would be taken against those trying to derail the efforts of the government to contain the virus spread, he said.

    A case has been registered against the accused, Deputy Superintendent of Police G S Bains said.

  • Onset of COVID-19 pandemic has led to paradigm shift in court functioning: SC judge

    Justice Nageswara Rao flagged the issue of digital divide, and said professionals have to shun their reluctance to adapt to use of new technology.

  • Our vaccine highly effective on COVID-19 variant prevalent in India, suitable for 12 years and above: Pfizer to government

    By PTI
    NEW DELHI: Seeking a fast-track approval for its COVID-19 vaccine, US major Pfizer has told Indian authorities that its jab has shown “high effectiveness” against the SARS-CoV-2 variant prevalent in India and on people of Indian ethnicity or nationality, while it is suitable for everyone aged 12 years or above and can be stored for a month at 2-8 degrees, sources said on Wednesday.

    Pfizer, which is ready to offer 5 crore doses to India between July and October this year and has sought certain relaxations including indemnification, has held a series of interactions with the Indian government authorities recently including one this week, during which it shared the most recent data points regarding efficacy trials and approvals for its vaccine in various countries and by the World Health Organisation (WHO).

    “The current situation in India, and across the world, is not ‘business as usual’ and we must not respond to it with processes as usual too,” a source quoted Pfizer as having communicated to the Indian government.

    ALSO READ: Moderna’s single-dose COVID-19 vaccine in India likely next year; Pfizer ready with 5 crore doses for 2021

    Another source privy to the discussions said that following recent meetings between the Indian government and Pfizer’s Chairman and CEO Albert Bourla, they have agreed to jointly work on three key issues to accelerate approval for the company’s COVID-19 vaccine in India, namely procurement through a central government pathway; indemnity and liability; and the regulatory requirement for post-approval bridging studies.

    While India has administered over 20 crore doses so far since the launch of its vaccination drive in mid-January, it is still a long way to reach the vaccination for the entire population, more so in the backdrop of many states having flagged shortage of vaccines and the gap between supply and requirement widening amid the deadly second wave.

    India is currently using mainly two ‘made-in India’ jabs Covishield manufactured by the Serum Institute and Covaxin of Bharat Biotech and Russian-made Sputnik V at a smaller scale to inoculate its population, all of which are approved only for those aged 18 years and above.

    ALSO READ: Moderna says its COVID-19 vaccine works in kids as young as 12

    In its latest communication to the government, Pfizer has also thanked the Government of India to have agreed to its request for procurement through a central government pathway and to discuss “the Indemnity and Liability protection”.

    “The timely alignment and execution of the draft Heads of Terms will enable Pfizer to reserve the allocation of doses and pave the pathway for executing the Distribution and Supply Agreement,” the company told the government while seeking fast-tracking the regulatory pathway to help it supply “Pfizer’s COVID-19 vaccine as expeditiously as possible to India”.

    Pfizer has said India should “rely on the 44 authorizations, including WHO approval, facilitate a EUA (Emergency Use Authorisation)/Restricted Use pathway for the Pfizer vaccine in India, and not seek a local PSA (Post Approval Commitment) study.”

    The company is, however, open to considering safety surveillance of the first 100 subjects after understanding the process to be followed.

    It has also stated that the Pfizer vaccine has undergone significant development over the last six months which includes improvement in storage conditions at 208 degrees for over one month (31 days) at the site of vaccination.

    ALSO READ: After Moderna, Pfizer too says no to Punjab on vaccine supply, state urges Centre to intervene

    “Recent data points confirm the high effectiveness of BNT612b2 2-dose regimen against SARS-CoV-2 variants, and among individuals of Indian ethnicity,” Pfizer has said.

    Providing data, it said UK’s Public Health England (PHE) has reported high vaccine effectiveness (87.9 per cent) against the B.1.617.2 variant, most reported in India, in an observational study (concluded on May 22, 2021).

    It further said 26 per cent of study participants overall were of “Indian or British Indian” ethnicity, and also included Bangladeshi (1.4 per cent), Pakistani (5.9 per cent) and any other Asian background (5.7 per cent), indicating that the observed vaccine effectiveness applies to these groups as well.

    Also, the data from Qatar’s nationwide immunization program demonstrated high vaccine effectiveness -89 per cent against B.1.1.7 variant (first detected in the UK) and 75 per cent against B.1.351 variant (first detected in South Africa).

    It said 24 per cent of study participants were of Indian nationality (more than 6,000), and others included Nepalese (6-12 per cent), Bangladeshi (4-11 per cent), Sri Lankan (3-4 per cent), Pakistani (4-6 per cent), indicating that the observed vaccine effectiveness applies to these groups as well.

    Pfizer has urged the Government of India to rely upon WHO’s testing pathways of reliance on testing certificates from country of origin instead of mandating local testing and batch release stating will also help fast track vaccine introduction and prevent vaccine wastage.

    Pfizer has also shared the most recent data on BNT162b2 mRNA vaccine — the phase 3 clinical trial showing vaccine efficacy six months after the second dose from the pivotal registration trial, as also for variants in vitro neutralization, clinically efficacy data and real-world vaccine effectiveness against emerging variants of SARS-CoV-2.

    The data shared with Indian authorities also include “real-world evidence of BNT162b2 vaccine effectiveness and safety from national immunization programmes”.

    The shared datapoints include trials showing nearly 95 per cent effectiveness against COVID-19, 100 per cent efficacy against severe disease and also 100 per cent vaccine efficacy in 12-15-year-old adolescents.

  • Beyond comprehension why Haryana government has not convened all-party meet on COVID issue: Bhupinder Singh Hooda

    Bhupinder Singh Hooda said he has continuously tried to awaken the government and also tried to raise awareness among the people.

  • Moderna’s single-dose COVID-19 vaccine in India likely next year; Pfizer ready with 5 crore doses for 2021

    By PTI
    NEW DELHI: Moderna is expecting to launch a single-dose COVID-19 vaccine in India next year and is in talks with Cipla among other Indian firms, while another US giant Pfizer is ready to offer 5 crore shots in 2021 itself but it wants significant regulatory relaxations including indemnification, sources said on Tuesday.

    While Moderna has conveyed to Indian authorities that it does not have surplus vaccines to share in 2021, there are limited prospects of Johnson & Johnson exporting its jabs from the US to other countries in the near future, the sources privy to discussions added.

    Two rounds of high-level meetings chaired by the Cabinet Secretary were held last week on the availability of vaccines in the global as well as domestic markets as it was felt that there is an urgent need to procure the jabs at a time the country is reeling under an unprecedented second wave of COVID-19 and a widening gap between supply and requirement.

    ALSO READ: Moderna says its COVID-19 vaccine works in kids as young as 12

    Currently, the country is using two ‘made-in India’ jabs — Covishield and Covaxin — to inoculate its billion-plus population and has administered 20 crore doses since launching the world’s largest vaccination drive in mid-January.

    A third vaccine, Russian-made Sputnik V, has been approved by the government and is being used on a smaller scale at present.

    In the high-level meeting officials from the Ministry of External Affairs, NITI Aayog, Department of Biotechnology, Law Ministry and Health Ministry were present.

    It was discussed that Moderna doesn’t have surplus vaccines to share in 2021 and that it plans to launch its single-dose vaccine for the Indian market only in 2022, for which, they are in discussion with Cipla and other Indian companies, a source said.

    It is learnt that Cipla has already evinced interest in procuring 5 crore doses from Moderna for 2022 and has requested confirmation from the central government in respect of stability in regulatory requirements/policy regime.

    ALSO READ: After Moderna, Pfizer too says no to Punjab on vaccine supply, state urges Centre to intervene

    The Health Ministry has also been asked to take an early decision on Cipla’s request regarding support required by them for procurement of Moderna vaccines.

    In the case of Pfizer, the US pharma giant has indicated availability of 5 crore vaccine doses — 1 crore in July, 1 crore in August, 2 crore in September and 1 crore in October –for supply to India in 2021 and that it will deal only with Government of India and payment for vaccines will have to be made by GOI to Pfizer India.

    The central government will make its own arrangement for further channelization of procured vaccines in the domestic market.

    According to another source, for the supply of vaccines to India, Pfizer has asked for indemnification from the Government of India and a document in this regard has been received from Pfizer Inc.

    Further, Pfizer has also sought certain relaxations in the regulatory regime, including relaxation in the requirement of post-approval bridging trials and dispensing the requirement of testing their vaccines in CDL (Central Drugs Laboratory).

    ALSO READ: Now, Pfizer, Moderna refuse to sell COVID-19 vaccines to Delhi government directly

    Taking into consideration the track record of the company, similar arrangements done with other countries in the world and the current pandemic situation, an overall view may be taken to indemnify the company by the government, officials said but flagged that in case a view is taken to indemnify the company, similar demands may be made by other companies.

    As per the information furnished by Pfizer, around 116 countries in the world including the USA have signed the indemnification document.

    Further, considering that over 14.7 crore doses of Pfizer had been administered worldwide without any significant reports of adverse effects, a view needs to be taken to indemnify the company in order to supplement the availability of vaccines in India, officials discussed at one recent meeting.

    It was suggested that a decision on the issue of Pfizer Inc may be taken at the earliest and that NEGVAC (National Expert Group on Vaccine Administration for COVID-19) may hold a meeting immediately on these issues.

    At a press conference on Monday, in response to a question on states being unable to procure vaccines directly from Moderna and Pfizer, Health Ministry Joint Secretary Lav Agarwal had said, “Whether it is Pfizer or Moderna, at the Centre-level, we have been coordinating with them.”

    “Also, the order book of both Pfizer and Moderna is full so it depends on their surplus that how much they can provide in India…they will come back to the Centre and we will help in facilitation to states,” he said.

  • China could be behind second wave of COVID-19 in India: BJP leader Kailash Vijayvargiya

    By PTI
    INDORE: BJP General Secretary Kailash Vijayvargiya has said it is a “matter of discussion” if the second wave of COVID-19 in India was an outbreak or China had a hand in it.

    A video of Vijayvargiya’s speech at a function here went viral on Tuesday.

    “There is a second wave of COVID-19. It was an outbreak, or was it sent? It is a matter of discussion, because if any country in the world has challenged China, it is India…Prime Minister Narendra Modi has challenged (China),” the BJP leader is heard saying in the video.

    “We think this is a viral `war’ by China to harass our country, because the second wave of COVID-19 was reported only in India and not in neighbouring countries like Bangladesh, Pakistan, Sri Lanka, Bhutan and Afghanistan,” he said, speaking in Hindi.

    It could not be ascertained if he said ‘war’ or ‘vaar’ which means `blow/attack’ in Hindi.

    While the BJP leader could not be contacted for comment, some witnesses said he made these statements at an event organized by a trust to distribute oxygen concentrators on Monday.

    Opposition Congress said he should clarify what he wanted to say.

    “Does Vijayvargiya want to say that China has waged a biological war against India? He holds a responsible position in the BJP and he should make clear the intent behind his statement,” state Congress spokesperson Neelabh Shukla said.

    The negligence of the BJP-led Union government was responsible for the second wave, he alleged.

  • Bihar CM Nitish Kumar directs strict COVID test of people coming from Bengal by trains and buses

    By PTI
    PATNA: Bihar Chief Minister Nitish Kumar on Tuesday told officials to strictly conduct COVID test of passengers coming to the state by trains and buses from West Bengal having high positivity rate.

    Kumar gave this direction while conducting a virtual high-level meeting on the COVID situation with the health department officials as well as the district magistrates during the day.

    According to official sources the positivity rate of Bengal is more than 10 per cent.

    The Bihar chief minister said positivity rate is falling in the state but still clinical examination for coronavirus should be further scaled up.

    Positivity rate in Bihar which was in the excess of 10 per cent in the beginning of the month has dropped to around 3 per cent now.

    The chief minister emphasised on aggressive testing for infection in the rural areas.

    He told officials to pay special attention to spread of ther virus in rural areas.

    He instructed officials to conduct household survey for the infection in the rural areas.

    The chief minister said there should be no leniancy in providing medicines and taking carer of COVID patients recuperating in home isolation.

    Kumar ordered that ex-gratia amont of Rs 4 lakh should be paid to families of coronavirus victims without delay.

    Additional chief secretary Health Pratyaya Amrit briefed the meeting about latest situation of coronavirus in the state.

    Meanwhile, Bihar recorded 104 fresh COVID deaths on Tuesday, taking the toll to 4746.

    Total 3306 new cases were registered in the past 24 hours in the state spiking the tally of coronavirus cases to 6,95,726.

    Recovery rate of COVID patients has risen top 95.27 per cent in Bihar.

    The state has a total of 35129 active caseload at present.